Business Context and Reporting Period
Company: Evogene Ltd. (EVGN)
Filing Type: Form 20-F Annual Report
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Evogene is a computational biology company utilizing AI-driven platforms (MicroBoost AI, ChemPass AI, GeneRator AI) to accelerate product discovery in agriculture, human health, and industrial applications. Operations are conducted through subsidiaries including Lavie Bio (ag-biologicals), AgPlenus (ag-chemicals), Biomica (human microbiome therapeutics), and Casterra (castor seeds).
Corporate Action: A 1-for-10 reverse share split was effected on July 24, 2024, to regain compliance with Nasdaq listing requirements.
Key Financial Metrics
| Metric (USD in thousands) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Revenues | $8,511 | $5,640 | $1,675 |
| Operating Loss | $(22,210) | $(26,508) | $(26,941) |
| Net Loss | $(18,054) | $(25,954) | $(29,844) |
| Net Loss Per Share (Basic/Diluted) | $(2.89) | $(5.20) | $(6.44) |
| Cash and Cash Equivalents (Year End) | $15,301 | $20,772 | $28,980 |
| Working Capital | $4,600 (approx.) | N/A | N/A |
| Accumulated Deficit | $(274,071) | $(257,586) | $(233,707) |
Segment Performance (2024):
- Agriculture: Revenue $5.9M; Operating Loss $(9.3M)
- Industrial Applications: Revenue $2.2M; Operating Loss $(2.4M)
- Human Health: Revenue $0.1M; Operating Loss $(7.2M)
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 51.8% to $8.5M, driven by a new licensing and collaboration agreement with Bayer (AgPlenus) and increased castor seed sales (Casterra).
- Loss Reduction: Net loss decreased 30.4% to $18.1M. This improvement was primarily due to a $6.5M non-cash financing income from the remeasurement of warrants and pre-funded warrants issued in August 2024, and a reduction in R&D expenses following the cessation of Canonic Ltd. (medical cannabis) operations.
- Financing Activity: In August 2024, the company raised approximately $5.5M via a registered direct offering of ordinary shares and pre-funded warrants. This transaction resulted in significant non-cash financing income ($6.5M) and expenses ($2.7M) related to warrant valuation.
- Collaboration Changes: In November 2024, Lavie Bio announced the cancellation of its licensing agreement with Corteva, regaining full rights to the licensed bio-fungicide technology. The $5M advance payment received previously will not be repaid.
Guidance, Outlook, and Risks
Going Concern Assessment: Management identified conditions raising substantial doubt about the company's ability to continue as a going concern for the next 12 months due to a history of operating losses, negative operating cash flows ($19.7M in 2024), and an accumulated deficit of $274M. Management has approved a plan to alleviate this doubt, including headcount reductions, deferral of R&D programs, and cost preservation measures.
Outlook:
- Expect to continue developing product pipelines and initiating new collaborations in 2025.
- Focus shifting toward AI-powered drug discovery (ChemPass AI) in the pharma market.
- Exploring exit opportunities for certain subsidiaries.
Key Risks:
- Liquidity: Dependence on future equity or debt financings, which may not be available on favorable terms and could cause dilution.
- Geopolitical: Operations are based in Israel; ongoing conflicts (Hamas, Hezbollah, Iran) pose risks to employee safety, infrastructure, and business continuity.
- Commercialization: Significant uncertainty regarding the ability to achieve regulatory approvals and commercialize product candidates in agriculture and human health.
- Cloud Migration: Recent transition of technological engines to Google Cloud Platform introduces operational and cybersecurity risks.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $15.3M cash balance against the $19.7M annual operating cash burn and the effectiveness of the approved cost-cutting plan.
- Warrant Accounting: Confirm the sustainability of the $6.5M non-cash financing income derived from warrant remeasurement, which significantly reduced the reported net loss.
- Revenue Concentration: Assess reliance on major customers (Customer A/Corteva accounted for 41% of 2024 revenue; Customer B/Bayer accounted for 21%).
- Subsidiary Dilution: Review the impact of external financings in subsidiaries (e.g., ICL's $10M SAFE in Lavie Bio, SHC's investment in Biomica) on Evogene's consolidated ownership and future revenue recognition.
- Geopolitical Exposure: Evaluate the specific impact of the war in Israel on R&D timelines, employee availability (reservist duty), and insurance coverage.